IBI128

Innovent Biologics (Suzhou) Co. Ltd. · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	IBI128
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Tigulixostat (IBI128) vs Febuxostat in Gout (PHASE3)
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects (PHASE2)
A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IBI128 CI brief — competitive landscape report
IBI128 updates RSS · CI watch RSS
Innovent Biologics (Suzhou) Co. Ltd. portfolio CI